Answers are grounded in this paper and cite their sources.
Evidence highlights registration issues in 9 countries, suggesting improvements could enhance health outcomes.
Some life-saving MNCH products are not available because national registration processes are flawed. Consequently, governments and donors must invest in changes to streamline procedures to register vital medicines to protect the health of women and children. To maximise health outcomes, countries should prioritise the registration of products of public health importance, including MNCH medicines.
No takes yet. Share an insight, caveat, or question.
Briggs et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: